Étiquette : dopamine

Modern Clinical Research on LSD, Matthias E Liechti, 2017

Modern Clinical Research on LSD Matthias E Liechti Neuropsychopharmacology, 2017, 42, 2114–2127. doi : 10.1038/npp.2017.86   All modern clinical studies using the classic hallucinogen lysergic acid diethylamide (LSD) in healthy subjects or patients in the last 25 years are reviewed herein. There were five recent studies in healthy participants and one in patients. In a controlled setting, LSD acutely induced bliss, audiovisual synesthesia, altered meaning of perceptions, derealization, depersonalization, and mystical experiences. These subjective effects of LSD were mediated by the 5-HT2A receptor. LSD increased feelings of closeness to others, openness, trust, and suggestibility. LSD impaired the recognition of sad and fearful faces, reduced left [...]

Lire la suite

Cannabidiol Protects Dopaminergic Neuronal Cells from Cadmium, Jacopo Junio Valerio Branca et al., 2019

Cannabidiol Protects Dopaminergic Neuronal Cells from Cadmium Jacopo Junio Valerio Branca, Gabriele Morucci, Matteo Becatti, Donatello Carrino, Carla Ghelardini, Massimo Gulisano, Lorenzo Di Cesare Mannelli  Alessandra Pacini International Journal of Environmental Research and Public Health, 2019, 16, 4420. doi : 10.3390/ijerph16224420   Abstract The protective effect of cannabidiol (CBD), the non-psychoactive component of Cannabis sativa, against neuronal toxicity induced by cadmium chloride (CdCl2 10 M) was investigated in a retinoic acid (RA)-dierentiated SH-SY5Y neuroblastoma cell line. CBD (1 M) was applied 24 h before and removed during cadmium (Cd) treatment. In dierentiated neuronal cells, CBD significantly reduced the Cd-dependent decrease of cell viability, and the rapid [...]

Lire la suite

Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus Through Bi-Directional Control of ERK1-2 Phosphorylation, Roger Hudson et al., 2019

Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus Through Bi-Directional Control of ERK1-2 Phosphorylation Roger Hudson, Justine Renard, Christopher Norris, Walter J. Rushlow and Steven R. Laviolette The Journal of Neuroscience, 2019 https://doi.org/10.1523/JNEUROSCI.0708-19.2019   Abstract Evidence suggests that the phytocannabinoids Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) differentially regulate salience attribution and psychiatric risk. The ventral hippocampus (vHipp) relays emotional salience via control of dopamine (DA) neuronal activity states, which are dysregulated in psychosis and schizophrenia. Using in-vivo electrophysiology in male Sprague Dawley rats, we demonstrate that intra-vHipp THC strongly increases ventral tegmental area (VTA) DA neuronal frequency and bursting rates, decreases GABA frequency, and [...]

Lire la suite

The Role of Cannabis within an Emerging Perspective on Schizophrenia, Jegason P. Diviant et al., 2018

The Role of Cannabis within an Emerging Perspective on Schizophrenia Jegason P. Diviant, Jacob M. Vigil, and Sarah S. Stith Medicines, 2018, 5, 86, 1-11. doi : 10.3390/medicines5030086   Abstract Background : Approximately 0.5% of the population is diagnosed with some form of schizophrenia, under the prevailing view that the pathology is best treated using pharmaceutical medications that act on monoamine receptors. Methods : We briefly review evidence on the impact of environmental forces, particularly the effect of autoimmune activity, in the expression of schizophrenic profiles and the role of Cannabis therapy for regulating immunological functioning. Results : A review of the literature shows that phytocannabinoid consumption may [...]

Lire la suite

Why Psychiatry Needs 3,4 Methylenedioxymethamphetamine : A Child Psychiatrist’s Perspective, Ben SESSA, 2017

Why Psychiatry Needs 3,4 Methylenedioxymeth-amphetamine : A Child Psychiatrist’s Perspective Ben SESSA Neurotherapeutics, 2017, 14, (3), 741-749. doi:10.1007/s13311-017-0531-1 Abstract Since the late 1980s the psychoactive drug 3,4-methylenedioxymethamphetamine (MDMA) has had a well-known history as the recreationally used drug ecstasy. What is less well known by the public is that MDMA started its life as a therapeutic agent and that in recent years an increasing amount of clinical research has been undertaken to revisit the drug’s medical potential. MDMA has unique pharmacological properties that translate well to its proposed agent to assist trauma-focused psychotherapy. Psychological trauma—especially that which arises early in life from child abuse—underpins many [...]

Lire la suite

Psilocybin exerts distinct effects on resting state networks 1 associated with serotonin and dopamine in mice, Joanes Grandjean et al., 2019

Psilocybin exerts distinct effects on resting state networks 1 associated with serotonin and dopamine in mice Joanes Grandjean, David Buehlmann, Michaela Buerge, Hannes Sigrist, Erich Seifritz, Franz X. Vollenweider, Christopher R. Pryce, Markus Rudin Preprint · September 2019 Doi : 10.1101/751255   Abstract Hallucinogenic agents have been proposed as potent antidepressants; this includes the serotonin (5-HT) receptor 2A agonist psilocybin. In human subjects, psilocybin alters functional connectivity (FC) within the default-mode network (DMN), a constellation of inter-connected regions that is involved in self-reference and displays altered FC in depressive disorders. In this study we investigated the effects of psilocybin on FC in the analogue of the [...]

Lire la suite

Acute effects of delta 9-tetrahydrocannabinol (THC) on resting state brain function and their modulation by COMT genotype, Matthijs G. Bossong et al., 2019

Acute effects of delta-9-tetrahydrocannabinol (THC) on resting state brain function and their modulation by COMT genotype Matthijs G. Bossong, Hendrika H. van Hell, Chris D. Schubart, Wesley van Saane, Tabitha A. Iseger, Gerry Jager, Matthias J.P. van Osch, J. Martijn Jansma, René S. Kahn, Marco P. Boks, Nick F. Ramsey European Neuropsychopharmacology, 2019, 13, 56, 1–11 https://doi.org/10.1016/j.euroneuro.2019.03.010   Abstract Cannabis produces a broad range of acute, dose-dependent psychotropic effects. Only a limited number of neuroimaging studies have mapped these effects by examining the impact of cannabis on resting state brain neurophysiology. Moreover, how genetic variation influences the acute effects of cannabis on resting state brain function [...]

Lire la suite

Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats, Marcello Solinas et al., 2006

Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats Marcello Solinas, Zuzana Justinova, Steven R. Goldberg and Gianluigi Tanda Journal of Neurochemistry, 2006, 98, 408–419. doi:10.1111/j.1471-4159.2006.03880.x   Abstract Although endogenous cannabinoid systems have been implicated in the modulation of the rewarding effects of abused drugs and food, little is known about the direct effects of endogenous ligands for cannabinoid receptors on brain reward processes. Here we show for the first time that the intravenous administration of anandamide, an endogenous ligand for cannabinoid receptors, and its longer-lasting synthetic analog methanandamide, increase the extracellular dopamine [...]

Lire la suite

Cannabinoids in Parkinson’s Disease, Mario Stampanoni Bassi et al., 2017

Cannabinoids in Parkinson's Disease Mario Stampanoni Bassi, Andrea Sancesario, Roberta Morace, Diego Centonze, and Ennio Iezzi Cannabis and Cannabinoid Research, 2017, Volume 2.1 DOI: 10.1089/can.2017.0002 Abstract The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably complex and involve both the modulation of other neurotransmitters (c-aminobutyric acid, glutamate, opioids, peptides) and the activation of different receptors subtypes (cannabinoid receptor type 1 and 2). In the last years, experimental studies contributed to enrich this scenario reporting interactions between cannabinoids [...]

Lire la suite

Brain Imaging Studies on the Cognitive, Pharmacological and Neurobiological Effects of Cannabis in Humans : Evidence from Studies of Adult Users, Aviv Weinstein et al., 2016 .

Brain Imaging Studies on the Cognitive, Pharmacological and Neurobiological Effects of Cannabis in Humans : Evidence from Studies of Adult Users. Aviv Weinstein, Abigail Livny, Abraham Weizman. Current Pharmaceutical Design, 2016, 22, 42, 6366-6379. doi: 10.2174/1381612822666160822151323. PMID : 27549374 Abstract Cannabis is the most widely used illicit drug worldwide. Regular cannabis use has been associated with a range of acute and chronic mental health problems, such as anxiety, depression, psychotic symptoms and neurocognitive impairments and their neural mechanisms need to be examined. This review summarizes and critically evaluates brain-imaging studies of cannabis in recreational and regular cannabis users between January 2000 and January 2016. The [...]

Lire la suite